ALK and anaplastic large cell lymphoma: IL-9 and IL-22 activate oncogenic signaling via the JAK3-STAT3 pathway, and neutralizing antibodies against them may inhibit the survival and clonogenicity of ALK+ ALCL cells (27, 28).